Hosted on MSN

Aktis Oncology kicks 2026 IPO cycle off with $210m target

The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...

4 Watchpoints For 2026's Potential Mega IPO Class

Potential IPOs from SpaceX, OpenAI, and Anthropic could make 2026 a record year for U.S. IPO proceeds. The latest reported ...
Hosted on MSN

Goldman investment banking co-head Kim Posnett on the year ahead, from an IPO ‘mega-cycle’ to another big year for M&A to AI’s ‘horizontal disruption’

Ahead of the World Economic Forum‘s Annual Meeting in Davos, Switzerland, Fortune connected with Goldman Sachs’ global co-head of investment banking, Kim Posnett, for her outlook on the most urgent ...
Forbes

Breaking The 'Bro IPO' Cycle: CFOs As Diversity Champions

The IPO window has reopened, but diversity hasn’t followed suit. According to research performed by Free Float Analytics’ cofounder Damion Rallis, 88% of the 61 companies filing to go public in August ...